TFF Pharmaceuticals, Inc. announced the appointment of Thomas B. King to its Board of Directors. Mr. King has over 30 years of executive leadership and board experience in the life sciences industry. Presently, Mr. King sits on the board of several companies, including Achieve Life Sciences, Kinaset Therapeutics, and Concentric Analgesics.

From 2003 to 2016, Mr. King served as the President, Chief Executive Officer and Director of Alexza Pharmaceuticals, where he led multiple stock offerings and debt transactions from 2003 through 2015 (IPO in 2006), raising in excess of $600mm and ultimately leading to the successful M&A transaction with Grupo Ferrer. Prior to joining Alexza, he was the President, Chief Executive Officer and Director of Cognetix, Inc. From 1994 to 2000, Mr. King served in multiple executive roles and as a Director with Anesta Corp., where he led two successful follow-on stock offerings, NDA and MAA approvals for oral transmucosal fentanyl citrate (Actiq), and a successful M&A transaction with Cephalon in 2000. Earlier in his career, Mr. King served as Vice President of Marketing and Business Development with Somatogen, Inc., and before joining Somatogen, he served as Director of the Cardiovascular Business Unit at Abbott Laboratories, Pharma Products Division.

Mr. King received his B.A. degree in chemistry from McPherson College and an MBA from the University of Kansas Graduate School of Business.